Optimi Health Corp. (OPTH) Form 6-K — Oct 20, 2026
Optimi Health completed a new production batch of GMP-grade MDMA capsules at its Health Canada-licensed facility in Princeton, British Columbia. The batch will supply a proposed Canadian Phase 3 trial of MDMA-assisted therapy for PTSD in up to 100 veterans and frontline workers, expected to begin in 2027. The same batch also covers a commercial export to Australia planned before the end of 2026 and a clinical trial in Israel run by MAPS' Healing October 7th project, which received Israeli Ministry of Health approval.
Key figures
- Phase3 start
- 2027
- Phase3 enrollment
- up to 100 participants
- Commercial supply since
- 2024
- Australia shipment timing
- before end of 2026
- Australian clinicians trained
- 750+
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.